Physician profile
Felicity Mack
NPI 1356662134
$3,153.01
in general payments reported to CMS, 2019-2025
34 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $148 · 2021: $136 · 2022: $458 · 2023: $950 · 2024: $881 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $444.94 | 2022-2025 | Renasys Go V2 Home, Renasys Touch, Pico 7 |
| Mylan Specialty L.P. | $401.88 | 2020-2024 | Yupelri |
| Spinal Simplicity, LLC | $239.92 | 2023 | Ha Minuteman G3-R |
| Kerecis Limited | $209.40 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Abbvie INC. | $204.01 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $188.18 | 2020-2025 | Farxiga |
| Abbott Laboratories | $145.70 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Astellas Pharma US INC | $140.49 | 2023-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.43 | 2025 | Caplyta |
| Hartmann USA, INC. | $130.73 | 2023-2024 | Zetuvit Plus 10x10 P10, Zetuvit Plus |
| Tactile Systems Technology INC | $77.50 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Viatris Specialty LLC | $74.37 | 2025 | Yupelri |
| Dexcom, INC. | $62.87 | 2024-2025 | Dexcom G6 Transmitter |
| Amniox Medical, INC. | $61.10 | 2020 | |
| Paratek Pharmaceuticals, INC. | $57.73 | 2024-2025 | Nuzyra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.54 | 2023 | Lifevest |
| Alkermes, INC. | $49.08 | 2023 | Vivitrol |
| Insulet Corporation | $46.76 | 2025 | Omnipod |
| Kci USA, INC. | $46.16 | 2022 | |
| Pfizer INC. | $44.61 | 2023-2025 | |
| Novo Nordisk INC | $40.29 | 2023-2024 | Ozempic, Rybelsus, Tresiba |
| Ossur Americas, INC. | $38.43 | 2025 | |
| Edwards Lifesciences Corporation | $36.20 | 2024 | Sapien 3 Ultra Resilia |
| Lilly USA, LLC | $33.88 | 2024 | Mounjaro, Zepbound |
| Cochlear Americas | $31.80 | 2023 | Baha, Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Otsuka America Pharmaceutical, INC. | $30.82 | 2023-2025 | Rexulti |
| Mimedx Group, INC. | $19.85 | 2024 | |
| Convatec INC. | $19.68 | 2023 | |
| Aroa Biosurgery Incorporated | $19.23 | 2024 | |
| Exact Sciences Corporation | $16.24 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $15.69 | 2020 | |
| Gilead Sciences, INC. | $14.80 | 2020 | |
| Medtronic Vascular, INC. | $14.77 | 2020 | |
| Ets Wound Care LLC | $13.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felicity Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.